MOLOGEN AG
MOLOGEN AG: dSLIM(R) shows superior immunoactivation capabilities
MOLOGEN AG / Key word(s): Study MOLOGEN AG: dSLIM(R) shows superior immunoactivation capabilities Berlin, April 08, 2014 – MOLOGEN AG has presented latest research results on its immunomodulator and TLR9 agonist dSLIM(R) in a poster presentation at the American Association for Cancer Research (AACR) 2014 Meeting in San Diego. The results show that the unique conformation of MOLOGEN’s dSLIM(R) molecule leads to superior cancer-fighting immunoactivation compared to other TLR9 agonists. DNA-based TLR9 agonists are potent activators of immune cell populations and the immune system. The poster presentation reported results from a comparison of dSLIM(R) with a different TLR9 agonist, representing the classes of TLR9 agonists with linear DNA molecules. dSLIM(R) establishes a new class of TLR9 agonists, represented by covalently closed dumbbell-like DNA molecules consisting entirely of natural DNA components with two single-stranded CG-containing loops separated by a double-stranded stem. In contrast to dSLIM(R), all known classes of TLR9 agonists are made of linear DNA molecules containing non-natural DNA modifications. dSLIM(R) is the active ingredient of the drug candidate MGN1703 currently developed by MOLOGEN in oncology. In 2013 MGN1703 reported positive phase II data in colorectal cancer (CRC) and this year a phase III is planned in the same indication. Recently, a randomized study in small cell lung cancer started patient accrual. Poster Details: About MGN1703 About MOLOGEN AG With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies. MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. PRESS SERVICE: INVESTOR RELATIONS: External Investor Relations: Note about risk for future predictions
End of Corporate News 08.04.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
262170 08.04.2014 |